DARZALEX 20 mg/ml, concentrate for solution for infusion bottle, 5 ml
Active ingredients: Daratumumab
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Concentrate for solution for infusionbottle, 5 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DARZALEX 20 mg/mL, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 5 ml
- Marketing authorisation holder
- JANSSEN CILAG INTERNATIONAL NV
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 20 Jun 2016
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67352140CIP75502180CIP133400955021803Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DARATUMUMABsolution | 20 mg · 1 ml de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.